Skip to content

Finding a better nasal anaesthetic: the efficacy of tetracaine and oxymetazoline as a topical nasal anaesthetic and decongestant

The efficacy of tetracaine and oxymetazoline as a topical nasal anaesthetic and decongestant in healthy participants

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ANZCTR
Registry ID
ACTRN12622001123730
Enrollment
10
Registered
2022-08-16
Start date
2023-03-14
Completion date
2023-03-30
Last updated
2023-06-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

Cophenylcaine (a combination of lignocaine and phenylephrine, a local anaesthetic and decongestant respectively) is commonly used as a spray to make the inside of the nose numb in Otolaryngology (ear, nose and throat surgery) clinics. However, other local anaesthetics like tetracaine are more potent than lignocaine, and phenylephrine tastes very bitter whereas other decongestants like oxymetazoline are essentially tasteless. Our hypothesis is that a tetracaine/oxymetazoline spray will act more quickly and give better anaesthesia to the inside of the nose than cophenylcaine. We will test cophenylcaine and three different concentrations of tetracaine/oxymetazoline in ten healthy participants. We will give them two sprays of one anaesthetic/decongestant in one nostril, and two sprays of another anaesthetic/decongestant in the other nostril, and measure the sensation of the lining of the nose at regular intervals using fine hair-like filaments designed for this purpose. Then, we will do the same thing with the other two anaesthetic/decongestants at least one day later, so that all participants will receive all four anaesthetic/decongestants. This will show clearly whether tetracaine/oxymetazoline gives better nasal anaesthesia than cophenylcaine, and if so, which concentration of tetracaine is best for this purpose.

Interventions

Tetracaine 0.5% + oxymetazoline 0.05% spray (1 mg tetracaine, 0.1 mg oxymetazoline) Tetracaine 1% + oxymetazoline 0.05% spray (2 mg tetracaine, 0.1 mg oxymetazoline) Tetracaine 2% + oxymetazoline 0.05% spray (4 mg tetracaine, 0.1 mg oxymetazoline) 0.2 mL of each preparation will be given intranasally as a spray, as a single exposure. The absolute doses of each drug for this volume of each preparation are given above. Participants will be randomised to receive one of these sprays or cophenylcai

Tetracaine 0.5% + oxymetazoline 0.05% spray (1 mg tetracaine, 0.1 mg oxymetazoline) Tetracaine 1% + oxymetazoline 0.05% spray (2 mg tetracaine, 0.1 mg oxymetazoline) Tetracaine 2% + oxymetazoline 0.05% spray (4 mg tetracaine, 0.1 mg oxymetazoline) 0.2 mL of each preparation will be given intranasally as a spray, as a single exposure. The absolute doses of each drug for this volume of each preparation are given above. Participants will be randomised to receive one of these sprays or cophenylcaine (control) in each nasal cavity. This will be given by an investigator (either a specialist or advanced trainee in Otolaryngology Head and Neck Surgery) in two sittings at least one day apart so that each participant will receive all four sprays in a random order in a consistent, reproducible manner.

Sponsors

University of Auckland
Lead SponsorUniversity

Study design

Allocation
Randomised controlled trial
Intervention model
Crossover
Primary purpose
Treatment
Masking
Blinded (masking used) (Subject, Caregiver, Outcomes Assessor)

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years
Healthy volunteers
Yes

Inclusion criteria

Able and willing to provide informed consent to participate

Exclusion criteria

Unable to provide informed consent, or non-consenting Known hypersensitivity to constituents of the test solutions Pregnancy Acute unwellness Smoking Sinonasal or systemic disease affecting the sinonasal mucosa - Granulomatous disease - Vasculitis - Cystic Fibrosis - Ciliary dysmotility - Immune deficiency - Rhinosinusitis

Outcome results

None listed

Source: ANZCTR · Data processed: Feb 4, 2026